A detailed history of Kestra Advisory Services, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Kestra Advisory Services, LLC holds 16,285 shares of HALO stock, worth $778,260. This represents 0.01% of its overall portfolio holdings.

Number of Shares
16,285
Previous 4,961 228.26%
Holding current value
$778,260
Previous $259,000 259.46%
% of portfolio
0.01%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$51.3 - $64.42 $580,921 - $729,492
11,324 Added 228.26%
16,285 $931,000
Q2 2024

Aug 14, 2024

BUY
$37.81 - $52.4 $187,575 - $259,956
4,961 New
4,961 $259,000
Q4 2022

Jan 31, 2023

BUY
$40.06 - $59.44 $211,717 - $314,140
5,285 New
5,285 $300,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.66B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Kestra Advisory Services, LLC Portfolio

Follow Kestra Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kestra Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kestra Advisory Services, LLC with notifications on news.